JMP Securities raised the firm’s price target on Skyward Specialty Insurance to $50 from $47 and keeps an Outperform rating on the shares. Skyward Specialty reported strong Q2 results, marking another strong growth quarter as the hard market in many specialty and E&S lines shows little sign of weakening and strong growth was again shown in the non-P&C areas of the business, the analyst tells investors in a research note. The firm thinks the well-diversified, low-volatility portfolio may be underappreciated by the market.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKWD:
- Is SKWD a Buy, Before Earnings?
- Skyward Specialty Achieves “A” (Excellent) Rating Upgrade by AM Best
- Skyward Specialty Recruits Julie Miglin to Lead New Life Sciences Unit and Steven Smith to Lead Transactional E&S Property Portfolio
- Skyward Specialty Insurance initiated with a Perform at Oppenheimer
- Skyward Specialty to Host Second Quarter 2024 Earnings Call Tuesday, August 6, 2024
